# Multiple myeloma Phase 3 clinical trial developments > Developing situation record from CLSTR: https://clstr.news/situations/multiple-myeloma-phase-3-clinical-trial-developments > Updated: 2026-10-27T11:39:41.000Z. Sources: 3. Developments: 2. Recent clinical developments in multiple myeloma treatment have seen positive Phase 3 trial results from major pharmaceutical companies. Bristol Myers Squibb reported that its Zenbexus regimen, used in combination with daratumumab and dexamethasone, met the second primary endpoint of progression-free survival in the EXCALIBER-RRMM trial. In patients with relapsed or refractory multiple myeloma, the regimen demonstrated a median progression-free survival of 42 months, compared to 20 months for the control group. Pfizer announced that its treatment, Elrexfio, met the primary endpoint in the MagnetisMM-32 Phase 3 trial. The study, which involved 523 adults across 26 countries, focused on patients who had previously received anti-CD38 therapy and lenalidomide. Results indicated an estimated 18-month progression-free survival rate of 68%, with Elrexfio reducing the risk of disease progression or death compared to control regimens. ## Timeline ### 2026-10-27: Pfizer reports positive Phase 3 trial results for Elrexfio in myeloma Pfizer’s Elrexfio met its primary endpoint in a Phase 3 trial for multiple myeloma, showing improved progression-free survival in patients treated earlier than current indications allow. 3 sources. https://clstr.news/cluster/pfizer-reports-positive-phase-3-trial-results-for-elrexfio-in-myeloma ### 2026-10-09: Bristol Myers Squibb reports positive Phase 3 results for Zenbexus in myeloma trial Bristol Myers Squibb’s Phase 3 EXCALIBER-RRMM trial shows Zenbexus combination therapy reduces the risk of disease progression or death by 51% in relapsed or refractory multiple myeloma patients. 2 sources. https://clstr.news/cluster/bristol-myers-squibb-reports-positive-phase-3-results-for-zenbexus-in-myeloma-trial --- Cite as: Multiple myeloma Phase 3 clinical trial developments. CLSTR, https://clstr.news/situations/multiple-myeloma-phase-3-clinical-trial-developments